Barclays analyst Brandon Oglenski lowered the firm’s price target on RXO Inc. (RXO) to $17 from $18 and keeps an Overweight rating on the shares following the Q2 report. The company continues to make progress in operation expense and purchased transportation synergies, but a “tepid” freight market, reduced throughput in automotive end markets and limited spot market opportunities will likely limit earnings upside in the second half of 2025, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXO:
- RXO Inc. price target raised to $16 from $15 at TD Cowen
- RXO Inc. price target raised to $15 from $14 at UBS
- RXO, Inc.: Hold Rating Maintained Amid Stable Outlook and Modest Growth Expectations
- RXO, Inc.: Balancing Profitability Amid Market Challenges with a Hold Rating
- RXO, Inc. Reports Strong Q2 Performance Amid Market Challenges